VBL Therapeutics Provides Update on Long-Term Survival in Phase 2 Trials of Patients with Multiple Tumor Types
June 19, 2017 08:00 ET
|
VBL Therapeutics
TEL AVIV, Israel, June 19, 2017 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq:VBLT) provided an update on the long term status and survival of patients from three completed Phase 2 trials, which...
VBL Therapeutics Announces Appointment of Dr. Corinne Epperly as U.S. Chief Operating Officer
June 15, 2017 07:00 ET
|
VBL Therapeutics
TEL AVIV, Israel, June 15, 2017 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq:VBLT) today announced the appointment of Corinne Epperly, MD, MPH, as U.S. Chief Operating Officer. Dr. Epperly is an...
VBL Therapeutics to Present at Upcoming June Conferences
June 14, 2017 08:00 ET
|
VBL Therapeutics
TEL AVIV, Israel, June 14, 2017 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq:VBLT) today announced Prof. Dror Harats, CEO, will provide a corporate overview at the 2017 BIO International Convention...
VBL Therapeutics Awarded $2.5 Million Grant by the Israel Innovation Authority
June 08, 2017 07:00 ET
|
VBL Therapeutics
TEL AVIV, Israel, June 08, 2017 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq:VBLT) today announced that it has been awarded a grant of 8.75 million New Israeli Shekels (approximately $2.5 million)...
New Phase 2 Patient Data Presented at ASCO Strengthen the Evidence for Anti-Tumor Activity of VB-111 in Recurrent GBM
June 05, 2017 07:30 ET
|
VBL Therapeutics
TEL AVIV, Israel, June 05, 2017 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq:VBLT), today announced the presentation of new data demonstrating that treatment with VB-111 (ofranergene obadenovec)...